SCHEMBL5146342

SCHEMBL5146342

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccc(OC)c(OCc2ccccc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
BLM P54132 1/20 0.41
BCHE P06276 1/20 0.40
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135387 0.95 MEN1 (0.43) C5AR1MAPK1HSD17B10MEN1KMT2A
SCHEMBL5134880 0.95 MEN1 (0.43) C5AR1MAPK1HSD17B10MEN1KMT2A
SCHEMBL651343 0.94 C5AR1 (0.47) C5AR1MEN1KMT2ABCHETP53
SCHEMBL5135188 0.92 MEN1 (0.42) C5AR1MAPK1HSD17B10MEN1KMT2A
SCHEMBL5137523 0.91 MEN1 (0.47) C5AR1HSD17B10MEN1KMT2AKDM4E
SCHEMBL5135719 0.90 KDM4E (0.41) C5AR1MAPK1HSD17B10MEN1KMT2A
SCHEMBL5135242 0.89 C5AR1 (0.45) C5AR1MEN1KMT2AKDM4EBCHE
SCHEMBL651011 0.89 C5AR1 (0.47) C5AR1HSD17B10MEN1KMT2AKDM4E
SCHEMBL647764 0.89 C5AR1 (0.47) C5AR1MAPK1HSD17B10MEN1KMT2A
SCHEMBL5136024 0.89 C5AR1 (0.41) C5AR1MAPK1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed